Navigation Links
EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
Date:10/25/2007

ies, ENMD-1198 has been shown to be an orally active, antimitotic agent that leads to arrest of cell division and apoptosis in tumor cells. ENMD-1198 also exerts antiangiogenic activity that further contributes to its overall antitumor effects.

Mark R. Bray, Ph.D., EntreMed Vice President, Research, commented on the results, "Preclinical studies with ENMD-1198 continue to highlight its significant antitumor activity. These data demonstrate that ENMD-1198 achieves predictable plasma drug levels after once daily oral dosing in humans, consistent with prior preclinical results."

Dr. Bray commented further, "The ENMD-1198 Phase 1 study continues in refractory solid tumor patients with a current dose level that is approaching the maximum tolerated dose in preclinical models without any ENMD-1198-related toxicity. Preclinical studies are continuing to help define Phase 2 indications and assess potential toxicities when used in combination with approved agents. These data further support ENMD-1198's potential for broad application in treating patients with cancer."

To view the poster presentation, visit the Company's web site at http://www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) NCD (2-methoxyestradiol or 2ME2) is currently in multiple Phase 2 clinical trials for cancer. MKC-1, an oral cell-cycle regulator, is in multiple Phase 1 and 2 studies for cancer. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. Panzem(R) is also in preclinical development for rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora-angiogenesis inhibitor, is in preclinical development for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and infl
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
5. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
6. EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models
7. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
8. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
9. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...20 Escalon Medical Corp....ts fiscal first quarter ended September 30, 2009. ...uct revenue decreased approximately $234,000, or 2...nded September 30, 2009 as compared to the same pe...ecreased net revenue of $8,434,000 compared with $...
(Date:11/20/2009)... 20 Cornerstone Therapeu...ical company focused on acquiring, developing and ... the respiratory and related markets, today report...Food and Drug Administration ("FDA") alleging that...Cl 10 mg, Pyrilamine Maleate 16 mg) and Deconsal D...
(Date:11/20/2009)...0 Medco Health Solutions...ansformation in American healthcare through an adv...ivering higher quality clinical care and fundament...icine smarter for the benefit of patients and payo...e elements in its strategy enable "Smarter Medicin...
Breaking Medicine Technology:Escalon(R) Reports First Quarter Fiscal 2010 Results 2Escalon(R) Reports First Quarter Fiscal 2010 Results 3Escalon(R) Reports First Quarter Fiscal 2010 Results 4Escalon(R) Reports First Quarter Fiscal 2010 Results 5Escalon(R) Reports First Quarter Fiscal 2010 Results 6Escalon(R) Reports First Quarter Fiscal 2010 Results 7Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal 2Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal 3Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 2Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 3Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 4Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 5Orion Health Live at Harley Street Clinic 48029 1Orion Health Live at Harley Street Clinic 48029 2Orion Health Live at Harley Street Clinic 48029 3Career Step Partners with Piedmont Community College to Help Students Gain Careers in Growing Healthcare Industry 48027 1Career Step Partners with Piedmont Community College to Help Students Gain Careers in Growing Healthcare Industry 48027 2Bruce Plaxen Named 2008 Maryland Trial Lawyer of the Year by Maryland Association for Justice 48025 1Bruce Plaxen Named 2008 Maryland Trial Lawyer of the Year by Maryland Association for Justice 48025 2
...ISCO, March 5 Atopic dermatitis, the common, chro...y rashes, has been increasing in prevalence over t... number of children. According to current estimate...ren in the United States and other industrialized ...is in the first few years of life. By comparison, ...
...arch 5 A study published by Deborah S. Sarnoff,... of Drugs in Dermatology explores the new genera...g technologies, specifically, the SmartXide DOT(TM...ve approach to treating the skin allowing for rapi.... Sarnoff is a board certified dermatologist and c...
Other Medicine Technology:Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children 2Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children 3Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children 4Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children 5New Study Published in the Journal of Drugs in Dermatology Finds DOT Microablative CO2 Laser Optimum for Skin Rejuvenation 2
(Date:11/21/2009)...Newswire/ -- A regional initiative launched in the...s) in the Americas has substantially reduced the p...nced by a 31% decrease in the number of individual...c countries. Results were reported today at the 5...ical Medicine and Hygiene (ASTMH). ,, The repo...
(Date:11/21/2009)...entialing software company IntelliSoft Group is th... Amerinet, Inc., the leading healthcare G.P.O. in ...quality care within the healthcare market. , ...SG Group, LLC, doing business as IntelliSoft Group..., a leading national healthcare group purchasing o...
(Date:11/21/2009)...nt and chief executive officer of the Alzheimer,s ...tatement regarding the inclusion of cognitive impa...s for Medicare beneficiaries in "The Patient ...introduced last night: , ...Hall, president and chief executive officer of the...
(Date:11/20/2009)...erstanding Brain Wiring and Diseases ,, WASHING... Schmahmann, Professor of Neurology at Harvard Med...eneral Hospital in Boston, on Thursday, November 1...field of study called "Connectivity" at the launch...is an award-winning leader in the field of the cer...
(Date:11/20/2009)...-USNewswire/ -- The United States Conference of Ca...changes its health reform bill in order to keep in...nce protection on abortion, protect access to heal...ns for adequate affordability. ,, The bishops c...appointment" that creates new and unacceptable fed...
Breaking Medicine News(10 mins):Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 3Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 4Health News:IntelliSoft Group and Amerinet Inc. Form Partnership to Transform Healthcare Delivery of Quality Patient Safety and Care 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 3Health News:MINDlink Foundation Launches to Connect the Cerebellum to Cures 2Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2
...ative herbicide tolerant systems and ...EIM, Germany, Nov. 26 Bayer CropScience AG, Merte...at they have entered into a,longterm collaboration...ket with the opportunity to expand to other,soybea...
...vation and Effective Marketing ...PRNewswire-FirstCall/ -- Vitasoy,International Hol...: 0345),a Hong Kong- based manufacturer and distri...lion. The Group recorded a,profit attributable to ...
... Writer Suzanne Smalley looks at,GOP presidential ...s that,explain his moral code, which is at once ri...e roots of Giuliani,s outsized, complex adult pers...,strict moral code but always holding out the poss...
...,shopping season is underway and many Americans ma...ucts they buy -- many of which are imported. With,...Mike Leavitt will visit a,Los Angeles Toys"R"Us st...Plan,developed by an intra-governmental Import Saf...
...brate National,Family Caregivers Month, honoring t...edical support to loved ones who are ill or disabl...ts and their caregivers may find it,difficult to g...report from Pfizer (NYSE: PFE ) at:, http://media...
...e on Proposed Plan of Arrangement with ...PRNewswire-FirstCall/ - Aspreva Pharmaceuticals,Co...ed that meeting materials,regarding a special meet...d optionholders of record. Copies of the,meeting m...
Other Medicine News:Health News:Bayer CropScience, Mertec and M.S. Technologies to Co-Develop New Soybean Trait Products 2Health News:Bayer CropScience, Mertec and M.S. Technologies to Co-Develop New Soybean Trait Products 3Health News:Vitasoy Recorded Healthy Sales Growth for 1H FY2007/2008 2Health News:Vitasoy Recorded Healthy Sales Growth for 1H FY2007/2008 3Health News:Vitasoy Recorded Healthy Sales Growth for 1H FY2007/2008 4Health News:Vitasoy Recorded Healthy Sales Growth for 1H FY2007/2008 5Health News:NEWSWEEK: Media Lead Sheet/December 3, 2007 Issue (on newsstands Monday, November 26). 2Health News:NEWSWEEK: Media Lead Sheet/December 3, 2007 Issue (on newsstands Monday, November 26). 3Health News:NEWSWEEK: Media Lead Sheet/December 3, 2007 Issue (on newsstands Monday, November 26). 4Health News:Aspreva Sends Materials for Special Meeting to be Held December 17 2Health News:Aspreva Sends Materials for Special Meeting to be Held December 17 3Health News:Aspreva Sends Materials for Special Meeting to be Held December 17 4
RT-600
...ractor. The RT-300's accessory knob is positioned ...ols are within a hand's breadth of each other. Cyl...5 to -19.00D. "Sure-grip" knurls on the control kn...venient placement of the controls themselves, this...
Ultramatic RX Master PHOROPTOR Refracting Instrument - Plus Cylinder Black
Double Maddox
Medicine Products: